Meeting
2015 ASCO Annual Meeting
Veliparib (ABT-888) or placebo combined with carboplatin and paclitaxel in patients with previously untreated advanced/metastatic squamous (Sq) non-small cell lung cancer (NSCLC): A randomized phase 3 trial.
Authors
Mark D. McKee
AbbVie Inc., North Chicago, IL
Mark D. McKee , Igor Bondarenko , Salih Zeki Guclu , Vera Gorbunova , Laszlo Urban , Philip Clingan , Krzysztof Leśniewski-Kmak , Julien Mazières , Suresh S. Ramalingam , Michelle Pedersen , Angela DeLuca , Caroline Nickner , Qin Qin , Vincent L. Giranda
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT02106546
Citation
J Clin Oncol 33, 2015 (suppl; abstr TPS8107)
DOI
10.1200/jco.2015.33.15_suppl.tps8107
Abstract #
TPS8107
Poster Bd #
429b
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
A protocol pre-specified interim overall survival (OS) analysis of GEMSTONE-302: A phase 3 study of sugemalimab (suge) versus placebo plus platinum-based chemotherapy (chemo) as first-line (1L) treatment for patients (pts) with metastatic non–small cell lung cancer (NSCLC).
First Author: Caicun Zhou
Poster
2020 ASCO Virtual Scientific Program
A phase III, open-label, randomized study of atezolizumab in combination with carboplatin + paclitaxel + bevacizumab compared with pemetrexed + cisplatin or carboplatin with stage IV non-squamous non-small cell lung cancer (NSCLC) with activating EGFR mutation or ALK translocation (ATLAS Trial).
First Author: Sehhoon Park
Poster
2020 ASCO Virtual Scientific Program
Checkmate 77T: A phase III trial of neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) followed by adjuvant nivo in resectable early-stage NSCLC.
First Author: Tina Cascone
Poster
2019 ASCO Annual Meeting
AtTEnd/ENGOT-en7: A multicenter phase III double-blind randomized controlled trial of atezolizumab in combination with paclitaxel and carboplatin in women with advanced/recurrent endometrial cancer.
First Author: Nicoletta Colombo